This is a wonderful population-based study… that makes us comfortable with the current recommendations. The issue of how frequently one or the other test should be used is an evolving area,” said George W. Sledge, Jr, MD. Dr. Sledge is ASCO Immediate Past President.

Dr. Sledge pointed out that this study mirrors a trend in oncology—that is, going from cytopathology to molecular techniques. “This trend will become increasingly important,” he commented. Dr. Sledge is Ballve-Lantero Professor of Oncology and Professor of Pathology and Laboratory Medicine at the Indiana University School of Medicine. ■

Financial Disclosure: Dr. Sledge reported no potential conflicts of interest.